MPO and systemic inflammatory response syndrome: Neutrophil elastase inhibitor sivelepristal sodium (112) and myeloperoxidase inhibitor PF-1355 (113) have demonstrated effectiveness in inhibiting NET formation, making them potential treatments for acute respiratory distress syndrome (ARDS) or systemic inflammatory response syndrome (SIRS) with acute lung injury (ALI) (114).